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I
nvasive meningococcal disease (IMD) is an epidemic
infectious disease highly influenced by climatic fac-
tors. Climate plays an important role in both the
spatial distribution of the disease and in the seasonality
of IMD as seen all over the world (1). It is mentioned as
one of the infectious diseases likely to be affected by
climate change in the Fourth Assessment report of the
Intergovernmental Panel on Climate Change (IPCC) (2).
IMD is an airborne disease with humans as its only
reservoir. Global warming will change precipitation levels
with a combination of more severe droughts in some
areas and more frequent heavy precipitation events in
others (2), and these are events likely to affect the
incidence and geographical distribution of IMD (1).
Effects suspected to be the result of climate change are
already evident on the distribution of IMD epidemics in
Africa (1, 3).
Research in the field of infectious diseases and climate
has focused on vector-borne diseases like malaria and
dengue fever (1, 48). Less is known about the effects of
climate on airborne diseases like IMD.
The aim of this review is to give an overview of the
current knowledge of how climate affects IMD and
to more thoroughly investigate the climate research
concerning IMD that has been published in the last
decade.
The disease and its prevention
IMD includes meningococcal septicaemia and meningo-
coccal meningitis. The disease is prevalent all over the
world. It is caused by Neisseria meningitidis, a gram-
negative coccoid bacteria. Treatment of IMD is still not a
major problem as N. meningitidis is sensitive to a number
of antibiotics, although betalactamase resistance is seen
in some parts of the world (912). Despite treatment,
417% of the patients die (1318) and 820% of the
survivors will suffer from lifelong sequelae like deafness,
cognitive impairment and other central nervous system
complications (1922). The age groups most susceptible
to the disease are young children, adolescents and young
adults (23, 24).
N. meningitidis can be divided into serogroups on the
basis of polysaccharide capsular antigens. The major
pathogenic serogroups are A, B, C, W135, X and Y (24,
25). There are differences between the serogroups, both
in virulence and in their capacity to cause epidemics.
Large-scale epidemics are mainly caused by serogroup
A, although serogroups W135 and C have also been
implicated in epidemics. Smaller outbreaks and singular
cases of the disease are more commonly caused by
serogroupsBandCandlessfrequentlybyotherserogroups
(24, 26, 27).
IMD is transmitted through respiratory secretion or
saliva. N. meningitidis is found mainly in the upper
respiratory tract (URT). Acquisition of the bacteria
can either be transient or result in colonisation of the
URTepithelium (carriage) or in invasive disease (24). The
epidemiology of IMD is complex due to the great number
of symptom-free carriers of the bacteria. In populations
studied, 270% of people have been found to be carriers
of the bacteria in their airways (24, 2830). In Africa,
carrier rates have been shown to be higher during
epidemics than in the endemic situation (24, 28, 30, 31)
and less frequent in small children than in adolescents
and adults (24, 31). Carriage of Neisseria plays an
important role in the epidemiology of the disease, a role
that is still not well understood (29, 32).
Vaccines exist for serogroups A, C, W135, X and Y
but no commercial vaccine has yet been produced for
serogroup B. Limitations of the vaccines are short
duration of immunity, 35 years, low immunogenity in
children under two years and no effect on carriage
of the bacteria (24, 25). New conjugate vaccines have
been developed for serogroups A and C, with prolonged
immunity, better immunological effect in young children
and with protective effects against carriage (24, 3336).
Epidemiology of invasive meningococcal
disease (IMD)
Meningitis belt
In 1963, the French physician Lapeyssonnie described a
geographically well-defined area in Sub-Saharan Africa
with an exceptionally high incidence of meningococcal
meningitis (37). This area, the classical meningitis belt
(Fig. 1), has seen epidemics of the disease at intervals of
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described epidemic in Africa was in Nigeria in 1905 (38).
The meningitis beltstretches from Ethiopia andtheSudan
inEastAfricatoMali,SenegalandGuineainthewest(38).
The most common cause of these epidemics is N. meningi-
tidis serogroup A (37, 38). In the epidemic years of 2002
2003,serogroupAwassubstitutedbyserogroupW135that
caused a large epidemic with its main focus in Burkina
Faso (3942), but since then serogroup A has been the
dominantpathogenagain(38).Inthe20022003serogroup
W135 epidemic, as well as in a serogroup A epidemic
starting in the Sudan and Chad in 1988, it has been
demonstratedthatonelikelysourceofintroductionofnew
meningococcal bacterial strains in the meningitis belt is
pilgrims returning from the Hajj in Saudi Arabia (4345).
In the last decades, African countries south of the belt
have experienced large IMD epidemics and there has
been an extension of the belt into countries like Togo,
Cameroon, Co ˆte d’Ivoire and Benin (3, 46, 47). In East
Africa, Kenya, Uganda and Tanzania have suffered large-
scale IMD epidemics (3, 18, 38, 4749). The health
impact of IMD in Africa makes the disease a main focus
for interventions by health agencies in the countries of
the meningitis belt. During epidemics in the 1990s an
incidence of 1,000 cases per 100,000 was seen (24). An
estimated 200,000 people were hit by the disease in the
serogroup A epidemic of 1996 (32, 49).
Outside the belt
IMD is a global disease seen in most countries of the
world. The incidence of the disease is however lower than
in the meningitis belt. In Europe it ranges between
0.2 and 14 cases per 100,000 and 0.24 per 100,000 in
USA (51). In most countries the disease is endemic with
small outbreaks, mainly in crowded settings like schools
and military establishments and is mainly caused by
serogroups B and C (24, 52). Changes in the epidemiol-
ogy of IMD due to the introduction of the serogroup
C conjugate vaccine are expected to be seen in the future
(51). Infrequently epidemics of serogroup A meningitis
have been seen outside Africa, for example, in China (53),
Nepal (54), India (55) and Russia (56).
Climate and invasive meningococcal disease
(IMD)
Two main features of the IMD are influenced by climatic
factors: the geographical distribution of high disease
incidence with large epidemics in the meningitis belt
and the seasonality of the disease seen globally. During
the last decade, with growing interest in the effects of
climate on health, a number of studies, spatial as well
as temporal, of climatic effects on IMD have been
conducted and models for predicting epidemics have
been proposed. The majority of these studies have
concerned IMD in Africa (3, 50, 5862).
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Fig. 1. The classic African meningitis belt.
Source: Control of epidemic meningococcal disease. WHO practical guidelines. 2nd edition 1998. WHO/EMC/BAC/98.3.
Available from: http://www.who.int/csr/resources/publications/meningitis/whoemcbac983.pdf
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Lapeyssonnie described the boundaries of the meningitis
beltasequivalenttotheannualrainfallisohyetsof300mm
inthenorth,and1,100mminthesouth,therebyindicating
that climatic factors are involved in the geographical
distribution (37). Subsequent research in the meningitis
belt have found that the optimal climate for transmission
of the disease is the savannah climate south of the Sahel,
with an annual precipitation index of 3001,100 mm,
extremely dry but warm winter seasons and a relatively
abrupt onset of the rainy season (3, 57). During the last
decade climate research concerning the geographical
distribution of IMD in Africa has made important
progress and has resulted in risk mapping models.
Risk mapping
In a study by Molesworth and colleagues (3) in 2002, the
spatial distribution of IMD epidemics in Africa occurring
between 1980 and 1999 was mapped using a dataset with
published and unpublished epidemics and surveillance
data of number of cases reported to the WHO (Fig. 2).
Maps showing the location and maximum incidence rates
of 144 epidemics in Africa were constructed. The maps
demonstrated that the riskof IMD epidemics is almost as
high in many geographical areas south of the meningitis
belt, like the Rift Valley and the Great Lakes region,
but that the maximum number of cases is higher in the
countries in the belt as compared to countries outside
the belt. In accordance with the suggested boundaries of
the meningitis belt proposed by Lapeyssonnie 40 years
previously, the risk map also demonstrated a striking
association between IMD epidemics and the 3001,100
rainfall isohyets in all of Africa, also outside the belt.
The risk models constructed by Molesworth and
colleagues have been further developed to investigate
the environmental factors driving the IMD epidemics
in Africa. In a study by Molesworth and colleagues
published in 2003 (58), they analysed the same IMD
epidemic and surveillance data as in (3) together with
information on climate variables like absolute humidity,
dust and rainfall, and data on land-cover type and
population density. They found that absolute humidity
and land-cover type were the climatic factors that best
correlated to IMD epidemics. Among other factors found
to be independently associated with IMD epidemics,
dust was especially interesting as the dustiness in the
meningitis belt increased dramatically due to the Sahelian
droughts of the 1970s and 1980s (58). The model also
demonstrated that climate zones not having distinct wet
and dry seasons, such as deserts and the humid and often
Fig. 2. Risk map for IMD. Districts and provinces experiencing meningococcal meningitis epidemics in Africa 19801999. After
Molesworth et al. (3). Available from: http://www.liv.ac.uk/researchintelligence/issue15/graphics/15/meningitis_01.gif
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to have epidemics than those with contrasting seasons
like the semi-arid savannah and grassland found in the
Sahel and eastern and southern Africa.
The risk model of Molesworth and colleagues was
evaluated in a prospective study of IMD epidemics in
Africa 20022004 by Savory and colleagues (59). They
found that only 59% of the 71 epidemics that occurred
during the time period were located within the meningitis
belt. Most of the new epidemic districts were however
located in areas geographically contiguous to the belt.
The epidemics in the meningitis belt had a significantly
higher mean number of cases than epidemics outside the
belt. The authors concluded that there is an extension
of the meningitis belt particularly into districts in
Co ˆte d’Ivoire, Togo, the Central African Republic and
Cameroon (59). The risk mapping of IMD provides a
tool for priority planning of vaccination campaigns, for
further research on climate effects on IMD in Africa and
a model that can be suitable for the development of early
warning systems (EWS) for the disease. It will also be an
important instrument for surveillance of the impact of
future climate change (57).
Seasonality
Lapeyssonnie also described the seasonality of the
disease, with the peak of epidemics during the dry winter
season. Frequently the epidemics ceased when the rainy
season started, to be resumed in the dry season of the
next year (37, 63, 64).
Subsequent studies have suggested low absolute hu-
midity (58) and the dry Harmattan winter winds (62) as
the main climatic driver behind the seasonality in the
meningitis belt. Sultan and colleagues found a strong
correlation between the maximum Harmattan wind index
and the onset of IMD epidemics in a study in Mali during
19942002 (62). They concluded that the seasonal rise in
meningitis cases corresponded to large-scale atmospheric
phenomena associated with the Sahelian dry season (62).
The peak of the IMD epidemics comes when the
absolute humidity is at its lowest and the epidemics
subside with rising humidity before the annual rain
period begins (28). In a study in Niger, Jackou-Boulama
and colleagues (65) found a negative correlation between
rainfall and IMD incidence. The IMD incidence fell when
the rain season began. In contrast, incidence of menin-
gococcal carriage has been found to rise with increasing
atmospheric humidity in a study by Mueller and collea-
gues (66) where they investigated carriage rates in the
non-epidemic year of 2003 in Burkina Faso. This result
stresses the complex role of carriers in the understanding
of IMD.
Many countries outside Africa, especially in the
Northern hemisphere, show a similar seasonal incidence
of the disease as in the meningitis belt (6771) with peak
incidence during the dry winter months, but the relation
between high incidence and low humidity seen in the
meningitis belt is not a consistent finding outside the
belt. In New Zealand a study showed that the incidence
of IMD increased with increasing humidity and cooler
temperatures, but declined, as in the meningitis belt, with
heavy rain (72). UK studies have shown that IMD
outbreaks are correlated with high humidity and rapid
changes in relative humidity before outbreaks (73, 74).
The proposed biological explanation for the climate
effects on IMD is that low humidity, dry winds and high
levels of dust in the air injures the barriers of the URT
mucosa, thus facilitating IMD (18, 48). N. meningitidis
can more easily penetrate injured mucosal membranes
and access the blood stream and the meninges, where
it causes disease (18). The mechanisms of interaction
between N. meningitidis and the mucosal epithelial cells
are well known (18, 75), but to my knowledge no studies
concerning the effects of climatic factors on the patho-
genesis and transmission of N. meningitidis in vivo have
been done, perhaps mainly due to the lack of a reliable
animal model for the bacteria (76).
Early warning systems (EWSs)
One of the main aims of EWSs for IMD is to predict
epidemics so that mass vaccination can begin in time
to curb the spread of disease (57, 59, 61). One tool for
identifying epidemics is the IMD case number thresholds
presented by WHO as an EWS in the year 2000. It
distinguishes between the usual annual rise in IMD
incidence and epidemics (77). To find climatic factors
that can predict IMD epidemics, Thomson and collea-
gues investigated a large number of environmental factors
in a study in Burkina Faso, Niger, Mali and Togo (61).
They found that land-cover type (savannah, grassland
and barren areas) was associated with IMD incidence,
rainfall and dust. Areas with barren land had the lowest
IMD incidence and highest dust levels, and in savannah
areas the rainy season started earlier and was more
intense than in grassland and barren areas. They could
also demonstrate that excess dust in October and a
rainfall deficit in January were the best predictors for
epidemics. Annual meningitis incidence anomalies (e.g.
early cases) at district level were significantly correlated
with monthly climate anomalies for rainfall and dust
in the pre, post and epidemic seasons, with stronger
relationship in savannah areas (57).
The performance of an EWS based on climate indices
has recently been investigated in a study by Yaka and
colleagues (60). They identified Burkina Faso and Niger
as the two countries with the highest risk of IMD
epidemics using data from a previously published study
by Broutin and colleagues (50). By computing meningitis
cases in the two countries with climate variables, they
found a significant correlation between IMD incidence
Helena Palmgren
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January, in Niger. In Burkina Faso the correlation was
not significant. This study stresses the importance of
including other variables than climate in future EWSs to
be able to predict epidemics.
Climate is a driving factor in the seasonality of the
disease and in the geographical distribution of IMD in
the meningitis belt, but climatic factors alone cannot
explain the high disease incidence in the meningitis belt or
the periodicity of epidemics. Immunity in the population,
carriage rates, vaccination coverage, social interactions
and the introduction of new strains of meningococci are
other main factors to be considered to fully understand
the dynamics of IMD in the meningitis belt (57, 61).
Discussion
The epidemiology of IMD is closely related to climatic
factors like air humidity, rainfall and dust (3, 58, 61, 65).
The disease is a special challenge to research in the field
of disease and climate change as it is spread all over
the world and in almost all types of climate zones. The
meningitis belt in the Sahel region of Africa has the
highest IMD incidence and large epidemics mainly
caused by serogroup A meningococci is one of the main
health issues for the countries in the belt (30, 78).
Pre-epidemic vaccination against serogroups A and
W135, the most common serogroups causing epidemics
inthemeningitisbelt,isfeasible,butthevaccineeffectonly
lasts for three to five years, although the new conjugate
vaccines now in the pipeline may improve that duration
(79, 80). To keep the population constantly immune to the
disease is too costly and demands a vaccination infra-
structure that does not yet exist in the countries involved.
Mass vaccination in the face of a current epidemic is often
done too late (81).
In Africa, 350 million people lives in areas at risk for
IMD epidemics (57, 58). Only 40 million doses of the new
conjugate A vaccine will be available during the first
years. Risk models could guide selection of priority areas
and demonstrate vaccination efficacy through surveil-
lance. They could also provide support for the control of
epidemics in areas where the population has not had
access to new vaccines (57).
Meteorological surveillance offers a possibility for
developing EWSs for epidemic preparedness (5559).
With the aid of EWSs, vaccination could be made more
effective. Attempts at EWSs have been promising but
need further refinement (5557). For future predictive
models to be effective, meteorological data must
be included in computations together with data on
population immunity, changes in population structure
and the dynamics of N. meningitidis carriers (57, 61).
There also needs to be an improvement of disease
surveillance data and weather forecasting data in the
African continent (57). It is also crucial that health
authorities in the countries at most risk for IMD
epidemics are interested in the implementation of EWSs
and that economic resources are allocated for them (82,
83, 85). In 2008, the University Corporation for Atmo-
spheric Research (UCAR), working with an international
team of health and weather organisations, launched the
Meningitis forecast project. The aim of the project is to
provide long-term weather forecasts to medical officials
in Africa to help reduce outbreaks of meningitis. The
forecasts will enable local health providers to target
vaccination programmes more effectively (see http://
www.ucar.edu/news/releases/2008/meningitis.jsp).
Future climate change and invasive meningococcal
disease (IMD)
In the 21st century the main projected climate changes in
Africa are warming, especially in sub-tropical regions and
a decrease in annual rainfall, especially in North Africa
and the northern parts of Sahara. By 2080, an increase of
58% of arid and semi-arid land in Africa is projected
(78). The Sahel, where the meningitis belt is situated, is
one of the regions in Africa most vulnerable to climate
change. The factors that determine the southern bound-
ary of the Sahara and rainfall in the Sahel have attracted
special interest among climate scientists because of the
extended drought experienced in this region in the 1970s
and 1980s (84). Not only warming and decreased rainfall
but also complex feedback mechanisms due to deforesta-
tion, land-cover change and changes is atmospheric dust-
loading are also playing a role, particularly for drought
persistence in the Sahel and its surrounding areas (78).
A likely scenario for the projected increase in tempera-
ture and decrease in rainfall is more frequent and longer
droughts and thereby a likely increase in the amount
of dust in the surface air, together with alterations of
atmospheric humidity. These climatic factors will most
likely have negative effects on IMD in the meningitis belt,
with epidemics of longer duration and maybe also higher
incidence. But the effects these climate changes may have
on the incidence of meningococcal carriage must also be
considered, as carriage incidence plays an important role
in the dynamics of IMD epidemics (24, 29, 31). This
makes constructing scenarios for IMD more complex,
especially as some previous studies have shown negative
correlations between carriage and air humidity (66).
Warming and reduced rainfall will also affect the land-
cover types in the region with extension of the savannah
southwards. Populations at the margin of the current
distribution of IMD will be particularly affected (3, 58).
The meningitis belt has already expanded (48, 58, 85, 86)
and countries south of the belt have suffered from
epidemics to an extent not previously reported, for
example, in Cameroon (46), Ghana (87) and Togo (88).
The population at risk of IMD epidemics is likely to
expand, but this prediction is uncertain as droughts
Meningococcal disease and climate
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dislocation (78).
Future research and surveillance
Expansion of the meningitis belt is already evident and is
likely to progress with climate change in Africa. Close
surveillance of IMD incidence in the areas bordering the
meningitisbelt,andofotherAfricancountrieswithsimilar
climates, for early detection of climate change effects is
therefore of uttermost importance (3). Further develop-
mentofexistingEWSswithinclusionofmoredemographic
data,dataonvaccinationcoverageandnaturalimmunityin
the populations and bacteriological surveillance data on
meningococcal strains, is necessary for predicting epi-
demics in time for massvaccination campaigns to be
effective (60). Further studies on the relation between
climatic factors and IMD, both in the meningitis belt in
AfricaandincountriesoutsidethebeltintheNorthernand
Southern hemisphere are needed, to be able to refine
knowledge on how climate affects both the carrier state
and the disease. Of special interest are epidemics outside
Africawithin the 3001,100 mm rainfall isohyets (57).
There are differences between different serogroups of
meningococci, both in virulence and in their ability to
cause epidemics, that need to be investigated to a greater
extent to better understand differences in epidemiology
between serogroup A in the meningitis belt and other
serogroups, mainly C and B in countries outside the belt
(24, 26, 27). Molecular biology studies are needed to
better understand the effects of climate on the binding
and penetration of N. meningitidis in mucosal mem-
branes. This includes development of tissue models and
animal models for N. meningitidis.
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